These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29570823)

  • 61. Squamous cell carcinoma of the sole in a patient with chronic graft-vs-host disease.
    Howe NR; Lang PG
    Arch Dermatol; 1988 Aug; 124(8):1244-5. PubMed ID: 3401029
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients.
    Williams K; Mansh M; Chin-Hong P; Singer J; Arron ST
    Clin Infect Dis; 2014 Apr; 58(7):997-1002. PubMed ID: 24363331
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Sclerodermatous Graft-Versus-Host Disease: A Rare Sequela of Hematopoietic Stem Cell Transplantation.
    Jabin M; Batta S; Mian M; Parekh P
    Cureus; 2023 Oct; 15(10):e47963. PubMed ID: 38034201
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Paclitaxel-loaded ethosomes®: potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses.
    Paolino D; Celia C; Trapasso E; Cilurzo F; Fresta M
    Eur J Pharm Biopharm; 2012 May; 81(1):102-12. PubMed ID: 22414731
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Squamous cell carcinoma of the oral cavity associated with graft-versus-host disease.
    Myoken Y; Sugata T; Iwato K
    Int J Oral Maxillofac Surg; 2012 Apr; 41(4):544-5. PubMed ID: 22103997
    [No Abstract]   [Full Text] [Related]  

  • 66. Adverse effects of voriconazole: Over a decade of use.
    Levine MT; Chandrasekar PH
    Clin Transplant; 2016 Nov; 30(11):1377-1386. PubMed ID: 27581783
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Development of multiple cutaneous squamous cell carcinomas during PUVA treatment for chronic graft-versus-host disease.
    Altman JS; Adler SS
    J Am Acad Dermatol; 1994 Sep; 31(3 Pt 1):505-7. PubMed ID: 8077484
    [No Abstract]   [Full Text] [Related]  

  • 68. Keratinocyte cancer and its precursors in organ transplant patients.
    Jenni D; Hofbauer GF
    Curr Probl Dermatol; 2015; 46():49-57. PubMed ID: 25561206
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tretinoin for the treatment of cutaneous graft-versus-host disease.
    Gryn J; Crilley P
    Bone Marrow Transplant; 1990 Apr; 5(4):279-80. PubMed ID: 2104506
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Polymyositis and systemic sclerosis symptoms as a clinical manifestation of a chronic graft versus host disease: a case report and literature review].
    Tuchocka-Piotrowska A; Puszczewicz M; Kołczewska A; Majewski D
    Pol Arch Med Wewn; 2006 Apr; 115(4):356-60. PubMed ID: 17078495
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Acral keratotic graft versus host disease simulating warts.
    Kossard S; Ma DD
    Australas J Dermatol; 1999 Aug; 40(3):161-3. PubMed ID: 10439530
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach.
    Ritchie SA; Patel MJ; Miller SJ
    Dermatol Surg; 2012 Oct; 38(10):1604-21. PubMed ID: 22646842
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease.
    Marcellus DC; Altomonte VL; Farmer ER; Horn TD; Freemer CS; Grant J; Vogelsang GB
    Blood; 1999 Jan; 93(1):66-70. PubMed ID: 9864147
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Conjunctival Lesion in a Patient With Ocular Graft-vs-Host Disease.
    Paley GL; Farooq AV; Lubniewski AJ
    JAMA Ophthalmol; 2017 Aug; 135(8):883-884. PubMed ID: 28494062
    [No Abstract]   [Full Text] [Related]  

  • 75. Many faces of graft-versus-host disease.
    Peñas PF; Zaman S
    Australas J Dermatol; 2010 Feb; 51(1):1-10; quiz 11. PubMed ID: 20148830
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation.
    Zwald FO; Spratt M; Lemos BD; Veledar E; Lawrence C; Marshall Lyon G; Chen SC
    Dermatol Surg; 2012 Aug; 38(8):1369-74. PubMed ID: 22551390
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Topical kinase inhibitors induce regression of cutaneous squamous cell carcinoma.
    Yang X; Daifallah AEM; Shankar S; Beer J; Marshall C; Dentchev T; Seykora F; D'Armas S; Hahn J; Lee V; Sabry HH; Farag AM; Seykora JT
    Exp Dermatol; 2019 May; 28(5):609-613. PubMed ID: 30762245
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients.
    Vadnerkar A; Nguyen MH; Mitsani D; Crespo M; Pilewski J; Toyoda Y; Bermudez C; Kwak EJ; Silveira FP; Clancy CJ
    J Heart Lung Transplant; 2010 Nov; 29(11):1240-4. PubMed ID: 20591690
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Chronic cutaneous graft-versus-host disease associated with multiple cutaneous squamous cell carcinomas.
    Brown SJ; Jackson GH; Reynolds NJ; Lawrence CM
    Clin Exp Dermatol; 2006 May; 31(3):472-3. PubMed ID: 16681614
    [No Abstract]   [Full Text] [Related]  

  • 80. [Triple secondary malignancy of gingiva, palate and esophagus after an allogeneic bone marrow transplantation for cutaneous T-cell lymphoma].
    Koharazawa H; Yamaji S; Takasaki H; Takabayashi M; Fujimaki K; Taguchi J; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2005 Jul; 46(7):496-500. PubMed ID: 16440741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.